Approval · Notice of Compliance 30402 · 2023
NOROMBY: Notice of Compliance 30402
Issued March 28, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 30402
- Date
- March 28, 2023
- Company
- Juno Pharmaceuticals Corp.Mississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Product Monograph update
- Canadian reference product
- LOVENOX / LOVENOX HP
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| NOROMBY | Not yet assigned | — |
| NOROMBY HP | Not yet assigned | — |
Medicinal ingredients
- ENOXAPARIN SODIUM 100 MG per ML
- ENOXAPARIN SODIUM 20 MG per 0.2ML
- ENOXAPARIN SODIUM 30 MG per 0.3ML
- ENOXAPARIN SODIUM 40 MG per 0.4ML
- ENOXAPARIN SODIUM 60 MG per 0.6ML
- ENOXAPARIN SODIUM 80 MG per 0.8ML
- ENOXAPARIN SODIUM 150 MG per ML
- ENOXAPARIN SODIUM 120 MG per 0.8ML